Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06414915
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-16
First Post:
2024-05-10
Brief Title:
Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation
Sponsor:
National Cancer Center China
Organization:
National Cancer Center China
Organization Data
Organization:
National Cancer Center China
Class:
OTHER
Study ID:
HMPL-012-SPRING-NEN110
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
National Cancer Center China
Lead Sponsor Class:
OTHER
Responsible Party:
Puyuan Xing
Responsible Party Title:
Chief Medical Officer
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
National Cancer Center China
Old Name:
None
Old Organization:
None